The TBX22 antibody is a tool used to detect and study the TBX22 protein, a member of the T-box family of transcription factors. TBX22 plays a critical role in embryonic development, particularly in craniofacial and palatal morphogenesis, as well as neural tube closure. Mutations in the TBX22 gene are linked to X-linked cleft palate with ankyloglossia (CPX), a genetic disorder characterized by craniofacial abnormalities. Researchers utilize TBX22 antibodies in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate its expression, localization, and interactions in tissues and cell lines. These studies help elucidate TBX22's regulatory mechanisms in developmental pathways and its association with congenital disorders. Commercially available TBX22 antibodies are typically produced in hosts like rabbits or mice using immunogens derived from recombinant TBX22 protein fragments or synthetic peptides. Validation steps ensure specificity and reliability for experimental use. Beyond basic research, TBX22 antibodies have potential diagnostic applications, aiding in genetic screening for craniofacial malformations or evaluating TBX22-related syndromes like Cayler craniofacial syndrome. Their use contributes to advancing understanding of developmental biology and may inform therapeutic strategies for congenital defects.